Holder evidence
50
SEC ownership of REPLIGEN CORP
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0000730272.
Lead holder
BlackRock, Inc.
13D/G signal
BlackRock, Inc.
Latest evidence
31 Mar 2026
- CIK
- 0000730272
- Symbol
- RGEN on Nasdaq
- Location
- Waltham, MA
- SEC evidence mix
- 13D/G and 13F
- Lead holder
- BlackRock, Inc.
- Latest large-stake holder
- BlackRock, Inc.
- Latest evidence date
- 31 Mar 2026
Issuer identity
Ownership snapshot
Ownership snapshot
Top shareholders of REPLIGEN CORP (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Lead holder
BlackRock, Inc.
13D/G signal
BlackRock, Inc.
Evidence rows
50
Latest as of
31 Mar 2026
13D/G
13F
Lead comparable stake: 9.3%
13D/G row: BlackRock, Inc.
Showing 1-8 of 50 holder rows.
Rank 1 holder
BlackRock, Inc.
13D/G
13F
- Ownership
- 9.3%
- Position
- $724.77M
Rank 2 holder
PRICE T ROWE ASSOCIATES INC /MD/
13D/G
13F
- Ownership
- 8.2%
- Position
- $753.73M
Rank 3 holder
FMR LLC
13D/G
13F
- Ownership
- 5.1%
- Position
- $473.74M
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| BlackRock, Inc. |
13D/G
13F
Company
|
9.3%
|
$724,772,059
5,198,107 shares
|
$0 | 31 Mar 2025 |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13D/G
13F
T. Rowe Price Associates, Inc. · Company
|
8.2%
|
$753,733,060
4,599,860 shares
|
+$191,767,488 | 31 Dec 2025 |
| FMR LLC |
13D/G
13F
Company
|
5.1%
|
$473,742,228
2,891,140 shares
|
$0 | 31 Dec 2025 |
| Roy T. Eddleman |
13D/G
Roy T. Eddleman Living Trust
|
4.8%
|
$377,254,217
2,705,689 shares
|
$0 | 31 Dec 2024 |
| Roy T. Eddleman Living Trust |
13D/G
|
4.8%
|
$443,354,200
2,705,689 shares
|
$0 | 31 Dec 2025 |
| UNITED CAPITAL FINANCIAL ADVISORS, LLC |
13F
Company
|
4.9%
|
$326,830,324
2,773,980 shares
|
— | 31 Mar 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13F
Company
|
4.3%
|
$282,356,926
2,396,511 shares
|
— | 31 Mar 2026 |
| VANGUARD PORTFOLIO MANAGEMENT LLC |
13F
Company
|
4.1%
|
$271,586,175
2,305,094 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$12,429,803.
Buys
$201,830
Insiders: 1
Sells
$12,631,633
Insiders: 4
Net
-$12,429,803
Shares: -85,650
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 1,800
Shares: 87,450
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 3,832 | $0 | $536,480 | -$536,480 |
| 3-6 | 0 | 275 | $0 | $44,275 | -$44,275 |
| 6-9 | 0 | 83,343 | $0 | $12,050,878 | -$12,050,878 |
| 9-12 | 1,800 | 0 | $201,830 | $0 | +$201,830 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-18 of 18 reporting-owner rows connected to REPLIGEN CORP. Open a relationship link for the CIK-to-CIK filing trail.
Rows
18
Lead holder
Anthony Hunt
Net 12M change
-$12,429,803
Latest report
14 May 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Anthony Hunt | Director | $11,130,078 | -$10,522,607 | -49% | Mixed | 02 Mar 2026 |
| Karen A. Dawes | Director | $10,935,581 | -$44,275 | -0.4% | Median | 14 May 2026 |
| Olivier Loeillot | Chief Executive Officer, Director | $7,594,440 | -$1,733,450 | -19% | Filing P/S | 21 Apr 2026 |
| Jon Snodgres | Chief Financial Officer | $5,499,867 | Mixed | 16 May 2023 | ||
| Glenn P. Muir | Director | $4,718,808 | Median | 14 May 2026 | ||
| Christine Gebski | SVP, Filtration & Chromatography | $4,478,619 | Mixed | 14 May 2024 | ||
| James Bylund | Chief Operating Officer | $3,488,544 | -$331,301 | -8.7% | Mixed | 05 Mar 2026 |
| Jason K. Garland | Cfo | $2,757,024 | Mixed | 05 Mar 2026 | ||
| Ralf Kuriyel | Senior VP, R&D | $2,752,907 | Mixed | 05 Mar 2026 | ||
| Martin D. Madaus | Director | $988,745 | +$201,830 | +26% | Median | 14 May 2026 |
| Brian Robb Douglass | Chief Product Officer | $940,792 | Median | 07 May 2026 | ||
| Manner Carrie Eglinton | Director | $643,415 | Median | 14 May 2026 | ||
| Nicolas Barthelemy | Director | $640,469 | Median | 14 May 2026 | ||
| Rohin Mhatre | Director | $590,749 | Median | 14 May 2026 | ||
| Violetta Hughes | Chief Accounting Officer | $526,655 | Mixed | 02 Sep 2025 | ||
| Konstantin Konstantinov | Director | $458,201 | Median | 14 May 2026 | ||
| Margaret Pax | Director | $354,756 | Median | 14 May 2026 | ||
| Thomas F. Ryan Jr. | Director | $214,368 | Mixed | 01 Mar 2022 |
Recent insider transactions for REPLIGEN CORP
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Reported value | Reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Martin D. Madaus | RGEN | Common Stock | Award | 17.8% | 995 | 6,581 | 14 May 2026 | Direct | ||
| Martin D. Madaus | RGEN | Stock Option (Right to Buy) | Award | 2,239 | 2,239 | 14 May 2026 | Direct | |||
| Konstantin Konstantinov | RGEN | Common Stock | Award | 34.4% | 995 | 3,889 | 14 May 2026 | Direct | ||
| Konstantin Konstantinov | RGEN | Stock Option (Right to Buy) | Award | 2,239 | 2,239 | 14 May 2026 | Direct | |||
| Manner Carrie Eglinton | RGEN | Common Stock | Award | 22.3% | 995 | 5,461 | 14 May 2026 | Direct | ||
| Manner Carrie Eglinton | RGEN | Stock Option (Right to Buy) | Award | 2,239 | 2,239 | 14 May 2026 | Direct | |||
| Rohin Mhatre | RGEN | Common Stock | Award | 24.8% | 995 | 5,014 | 14 May 2026 | Direct | ||
| Rohin Mhatre | RGEN | Stock Option (Right to Buy) | Award | 2,239 | 2,239 | 14 May 2026 | Direct | |||
| Margaret Pax | RGEN | Common Stock | Award | 49.4% | 995 | 3,011 | 14 May 2026 | Direct | ||
| Margaret Pax | RGEN | Stock Option (Right to Buy) | Award | 2,239 | 2,239 | 14 May 2026 | Direct | |||
| Glenn P. Muir | RGEN | Common Stock | Award | 2.55% | 995 | 40,051 | 14 May 2026 | Direct | ||
| Glenn P. Muir | RGEN | Stock Option (Right to Buy) | Award | 2,239 | 2,239 | 14 May 2026 | Direct | |||
| Karen A. Dawes | RGEN | Common Stock | Award | 1.08% | 995 | 92,816 | 14 May 2026 | Direct | ||
| Karen A. Dawes | RGEN | Stock Option (Right to Buy) | Award | 2,239 | 2,239 | 14 May 2026 | Direct | |||
| Nicolas Barthelemy | RGEN | Common Stock | Award | 22.4% | 995 | 5,436 | 14 May 2026 | Direct | ||
| Nicolas Barthelemy | RGEN | Stock Option (Right to Buy) | Award | 2,239 | 2,239 | 14 May 2026 | Direct | |||
| Glenn P. Muir | RGEN | Common Stock | Options Exercise | 6.65% | 2,434 | 39,056 | 07 May 2026 | Direct | ||
| Glenn P. Muir | RGEN | Stock Option (Right to Buy) | Options Exercise | 2,434 | 2,434 | 07 May 2026 | Direct | |||
| Brian Robb Douglass | RGEN | Common Stock | Tax liability | -4.01% | -334 | 7,985 | 07 May 2026 | Direct | ||
| Olivier Loeillot | RGEN | Common Stock | Sale | -6.6% | $536,480 | $140.00 | -3,832 | 54,246 | 21 Apr 2026 | Direct |
| Ralf Kuriyel | RGEN | Common Stock | Award | 35.8% | 5,284 | 20,062 | 05 Mar 2026 | Direct | ||
| Ralf Kuriyel | RGEN | Stock Option (Right to Buy) | Award | 5,669 | 5,669 | 05 Mar 2026 | Direct | |||
| Olivier Loeillot | RGEN | Common Stock | Award | 71.1% | 24,134 | 58,078 | 05 Mar 2026 | Direct | ||
| Olivier Loeillot | RGEN | Stock Option (Right to Buy) | Award | 25,890 | 25,890 | 05 Mar 2026 | Direct | |||
| James Bylund | RGEN | Common Stock | Award | 43.9% | 7,751 | 25,423 | 05 Mar 2026 | Direct | ||
| James Bylund | RGEN | Stock Option (Right to Buy) | Award | 8,315 | 8,315 | 05 Mar 2026 | Direct | |||
| Jason K. Garland | RGEN | Common Stock | Award | 62.8% | 7,751 | 20,092 | 05 Mar 2026 | Direct | ||
| Jason K. Garland | RGEN | Stock Option (Right to Buy) | Award | 8,315 | 8,315 | 05 Mar 2026 | Direct | |||
| James Bylund | RGEN | Common Stock | Tax liability | -0.35% | -62 | 17,672 | 04 Mar 2026 | Direct | ||
| James Bylund | RGEN | Common Stock | Award | 0.71% | 125 | 17,734 | 04 Mar 2026 | Direct | ||
| Ralf Kuriyel | RGEN | Common Stock | Tax liability | -0.28% | -42 | 14,778 | 04 Mar 2026 | Direct | ||
| Ralf Kuriyel | RGEN | Common Stock | Award | 0.85% | 125 | 14,820 | 04 Mar 2026 | Direct | ||
| James Bylund | RGEN | Common Stock | Tax liability | -12.1% | -2,433 | 17,609 | 02 Mar 2026 | Direct | ||
| Olivier Loeillot | RGEN | Common Stock | Tax liability | -4.53% | -1,610 | 33,944 | 02 Mar 2026 | Direct | ||
| Anthony Hunt | RGEN | Common Stock | Tax liability | -10% | -9,897 | 89,062 | 02 Mar 2026 | Direct | ||
| Jason K. Garland | RGEN | Common Stock | Tax liability | -5.48% | -715 | 12,341 | 02 Mar 2026 | Direct | ||
| Ralf Kuriyel | RGEN | Common Stock | Tax liability | -5.91% | -923 | 14,695 | 02 Mar 2026 | Direct | ||
| Brian Robb Douglass | RGEN | Common Stock | Tax liability | -2.59% | -221 | 8,319 | 02 Mar 2026 | Direct | ||
| James Bylund | RGEN | Common Stock | Tax liability | -6.87% | -1,478 | 20,042 | 27 Feb 2026 | Direct | ||
| Olivier Loeillot | RGEN | Common Stock | Tax liability | -0.96% | -344 | 35,554 | 27 Feb 2026 | Direct | ||
| Jason K. Garland | RGEN | Common Stock | Tax liability | -2.44% | -327 | 13,056 | 27 Feb 2026 | Direct | ||
| Ralf Kuriyel | RGEN | Common Stock | Tax liability | -2.76% | -444 | 15,618 | 27 Feb 2026 | Direct | ||
| Brian Robb Douglass | RGEN | Common Stock | Award | 36.6% | 2,288 | 8,540 | 31 Dec 2025 | Direct | ||
| Brian Robb Douglass | RGEN | Stock Option (Right to Buy) | Award | 2,143 | 2,143 | 31 Dec 2025 | Direct | |||
| Karen A. Dawes | RGEN | Common Stock | Sale | -0.3% | $44,275 | $161.00 | -275 | 91,821 | 17 Dec 2025 | Direct |
| Glenn P. Muir | RGEN | Common Stock | Options Exercise | 10.1% | 3,366 | 36,622 | 16 Dec 2025 | Direct | ||
| Glenn P. Muir | RGEN | Stock Option (Right to Buy) | Options Exercise | 3,366 | 3,366 | 16 Dec 2025 | Direct | |||
| Anthony Hunt | RGEN | Common Stock | Other | -1.98% | -2,000 | 98,959 | 04 Dec 2025 | Direct | ||
| Olivier Loeillot | RGEN | Common Stock | Sale | -16.4% | $1,196,970 | $170.00 | -7,041 | 35,898 | 25 Nov 2025 | Direct |
| James Bylund | RGEN | Common Stock | Sale | -9.24% | $331,301 | $151.21 | -2,191 | 21,520 | 18 Nov 2025 | Direct |
* indicates a reported price that failed the local validity check.